Introduction
============

Head and neck cancer, including cancers in oral cavity, pharynx (other than nasopharynx), and larynx, is the sixth most common cancer in the world (Parkin et al., [@B47]). It accounted for about 900,000 of cases and 300,000 deaths in 2008 (Ferlay et al., [@B17]). The 5-year survival rate was about 61% in the US for all sites (Altekruse et al., [@B2]) and 26 to 63% in Europe depending on the subsite (Berrino et al., [@B6]). The major risk factors for head and neck cancer are tobacco smoking and alcohol drinking (Hashibe et al., [@B23]). The interaction between tobacco smoking and alcohol drinking is greater than the expected multiplicative null with an overall attributable risk of 72% (Hashibe et al., [@B24]). Other risk factors include human papillomavirus (HPV) infection (IARC Working Group/Human Papillomaviruses, [@B35]), passive smoking (Lee et al., [@B36]), low body mass index (BMI; Gaudet et al., [@B19]), poor diet (World Cancer Research Fund/American Institute for Cancer Research, [@B61]), and family history of cancer (Negri et al., [@B41]).

Previous molecular epidemiological studies on head and neck cancer have examined single nucleotide polymorphisms (SNPs), focusing on metabolic and DNA repair genes (Sturgis and Wei, [@B57]; Hashibe et al., [@B25], [@B26]; Canova et al., [@B10]); however, very few SNP associations have been consistent for head and neck cancer risk. The heterogeneity may result from study design, e.g., population- or hospital-based controls, study sample size, and study populations, e.g., race/ethnicity (Hashibe et al., [@B25]; Lohmueller et al., [@B37]). The International head and neck cancer epidemiology (INHANCE) consortium is a collaboration of research groups leading large molecular epidemiology studies of head and neck cancer. Since larger sample sizes can increase the precision of the effect measure estimates and the ability to detect statistically significant moderate associations, we pooled data on SNPs that were genotyped in common across the INHANCE studies, to evaluate the associations between the SNPs in several pathways and the risk of head and neck cancer.

Materials and Methods
=====================

The INHANCE consortium (<http://inhance.iarc.fr/>) was established in 2004. Fourteen studies participating in the consortium contributed SNP data: France (Benhamou et al., [@B5]), Central Europe (Hashibe et al., [@B22]), Seattle (Schwartz et al., [@B52]; Huang et al., [@B33]), Iowa (Wang et al., [@B60]), North Carolina (Olshan et al., [@B43]), Los Angeles (Cui et al., [@B14]), Houston (Zhang et al., [@B64]), Puerto Rico (Hayes et al., [@B27]), Rome (Boccia et al., [@B7]), Western Europe (Canova et al., [@B10]), Heidelberg (Risch et al., [@B51]), Japan (Suzuki et al., [@B58]), Northeast US (Park et al., [@B46]), and India (Anantharaman et al., [@B3]). Descriptions of the individual studies are presented in the Table [A1](#TA1){ref-type="table"} in Appendix. To increase power, we included all controls selected for lung and kidney cancers in the Central Europe multicenter case--control study, in addition to the head and neck cancer controls. There were 6,694 head and neck cancer cases and 12,601 controls.

Cases and controls with missing data on age, sex, race/ethnicity, or SNP information, and cases with missing information on the site of origin of their cancer were excluded (779 cases and 1,957 controls). In total, 5,915 cases and 10,644 controls were included in the analysis. Among the cases, 1,901 were oral cancer, 1,751 were pharyngeal cancer, 440 were cancers of the oral cavity or pharynx not otherwise specified, 1,632 were laryngeal cancer and 191 overlapping or subsite missing.

Written informed consent was obtained from all study subjects and the investigations were approved by institutional review boards at each of the institutes involved. Questionnaires were collected from all the individual studies, to assess the comparability of the collected data and of the wording of interview questions among the studies. Each data item was checked for illogical or missing values and inconsistencies were resolved as necessary.

Details on harmonizing questionnaire data have been published previously (Hashibe et al., [@B23]). Briefly, the definitions for ever smoking and drinking are different across studies. We reclassified ever tobacco smokers as those who have smoked at least 100 cigarettes or 100 cigars or 100 pipes in their lifetime. In our previous analyses, drinking (≥3 alcoholic drinks/day) was associated increased HNC risks (Hashibe et al., [@B23]), we thus classified heavy drinkers as those who have consumed three or more alcoholic drinks per day.

Single nucleotide polymorphisms reported in more than two studies were included in the current pooled analyses. In total, 28 SNPs in cell cycle (*p21* Ser31Arg rs1801270 and *p53* Pro72Arg rs1042522), DNA repair (*ERCC2* Lys751Gln rs28365048, *MGMT* Leu84Phe rs12917, Ile143Val rs2308321, 171C \> T rs1803965, *OGG1* Ser326Cys rs1052133, *XRCC1* Arg194Trp rs1799782, Arg280His rs25489, Arg399Gln rs25487, and *XRCC3* Thr241Met rs861539), folate metabolism (*MTHFR* Ala222Val rs1801133 and Glu429Ala rs1801131), and carcinogen metabolism (*ADH1B* Arg48His rs1229984, *ADH1C* Ile350Val rs698, *CYP1A1* Ile462Val rs1048943, 3801T \> C E0322, *CYP2E1* 1054C \> T rs2031920, 1143A \> T rs6413432, 1293G \> C rs3813867, *EPHX1* Try113His rs1051740, His139Arg rs2234922, *GSTM1* null, *GSTM3* Mnl AGG deletion rs1799735, *GSTP1* Ile105Val rs947894, Ala114Val rs1799811, *GSTT1* null, *NQO1* Pro187Ser rs1800566) pathways were included. Hardy--Weinberg equilibrium was tested in the controls by study. SNPs which did not pass the test in a specific study were excluded from the analyses.

The associations between SNPs and head and neck cancer risk were assessed by estimating odds ratios (OR) and 95% confidence intervals (CI) with unconditional logistic regression models for each study. The models included age (categories), sex, race/ethnicity (categories), and country (categories). In the Central Europe study, information on ethnicity was not collected and all subjects were classified as non-Hispanic white, since the majority of these populations were expected to be white. Pooled ORs were estimated with a fixed effects and random effects (DerSimonian and Laird, [@B15]) logistic regression model. We assessed heterogeneity across studies by the likelihood ratio test. Stratified analyses were conducted by cancer site (oral, pharynx, oral/pharynx not specified, and larynx), age (\<45 and ≥45 years), sex, race (White, Black, Hispanic, and Asian) geographic region (Europe, North America, and Latin America), study type (hospital-based and population-based), study size (\<300 cases and ≥300 cases), smoking (never and ever), drinking \[≤3 and \>3 drinks/day (Hashibe et al., [@B23])\] and fruit and vegetable intake (lower and higher than center-specific median among controls). The analyses were performed using SAS 9 and significant associations were defined as a two-sided *p*-value less than 0.05.

False positive report probability (FPRP; Wacholder et al., [@B59]) was assessed for all associations in which the two-sided null *p*-value was less than 0.05. FPRP was assessed for OR = 1.5 for probability of true association were 0.25, 0.1, 0.01, and 0.001. For the haplotype analysis, we selected the studies that had information on the multiple SNPs for the gene. We used PHASE v2. (Stephens et al., [@B55]; Stephens and Donnelly, [@B54]) to reconstruct the haplotype for genes with multiple SNPs available. Overall, haplotypes for four genes, *CYP2E1*, *EPHX1*, *GSTP1*, and *MTHFR*, could be reconstructed. The most frequent haplotype was treated as the referent group.

Results
=======

A total of 5,915 cases and 10,644 controls were pooled from 14 studies in Europe (2,759 cases and 4,629 controls), North America (2,234 cases and 3,290 controls), Central America (147 cases and 149 controls), and Asia (775 cases and 2,576 controls). Demographic characteristics of the cases and controls are presented in Table [1](#T1){ref-type="table"}. Among the cell cycle and DNA repair SNPs, we observed associations between head and neck cancer risk and *MGMT* Leu84Phe heterozygotes (OR = 0.79, 95% CI = 0.68--0.93) and *XRCC1* Arg194Trp rare homozygotes (OR = 2.3, 95% CI = 1.1--4.7; Table [2](#T2){ref-type="table"}).

###### 

**Demographic characteristics of head and neck cancer cases and controls**.

                                    Cases   Controls           
  ---------------- ---------------- ------- ---------- ------- ------
  All                               5915               10644   
  **SEX**                                                      
  Female                            1251    21.1       2765    26.0
  Male                              4664    78.9       7879    74.0
  **AGE**                                                      
  ≤44                               655     11.1       1545    14.5
  45--49                            628     10.6       1117    10.5
  50--59                            2014    34.0       3333    31.3
  60--69                            1664    28.1       2991    28.1
  70+                               954     16.1       1658    15.6
  **RACE**                                                     
  White                             4676    79.1       7298    68.6
  Black                             267     4.5        383     3.6
  Hispanic                          117     2.0        273     2.6
  Asian                             811     13.7       2647    24.9
  Others                            44      0.7        43      0.4
  **STUDY**        **COUNTRY**                                 
  France           France           256     4.3        173     1.6
  Central Europe   *Romania*        103     1.7        185     1.7
                   *Poland*         189     3.2        814     7.6
                   *Russia*         303     5.1        805     7.6
                   *Slovakia*       40      0.7        196     1.8
  Seattle          USA              360     6.1        560     5.3
  Iowa             USA              366     6.2        330     3.1
  North Carolina   USA              174     2.9        196     1.8
  Los Angeles      USA              320     5.4        915     8.6
  Houston          USA              828     14.0       865     8.1
  Puerto Rico      Puerto Rico      147     2.5        149     1.4
  Rome             Italy            277     4.7        293     2.8
  Western Europe   Czech Republic   111     1.9        152     1.4
                   Germany          175     3.0        179     1.7
                   Greece           190     3.2        160     1.5
                   Italy            378     6.4        446     4.2
                   Ireland          17      0.3        16      0.2
                   Norway           110     1.9        137     1.3
                   UK               236     4.0        301     2.8
                   Spain            76      1.3        81      0.8
                   Croatia          52      0.9        46      0.4
  Heidelberg       Germany          246     4.2        645     6.1
  Japan            Japan            320     5.4        1848    17.4
  Northeast US     USA              186     3.1        424     4.0
  India            India            455     7.7        728     6.8

###### 

**Cell cycle and DNA repair SNPs and the risk of head and neck cancer in the INHANCE consortium**.

  Gene    SNP rs number   Alteration   Referent genotype   No. Of cases   No. Of controls   Analysis model   Heterozygotes   Rare homozygotes                                        
  ------- --------------- ------------ ------------------- -------------- ----------------- ---------------- --------------- ------------------ --- ------ ------ -------------- --- ------
  P21     rs1801270       Ser31Arg     Ser/Ser             2301           3920              Fixed effects    1.11            (0.94--1.30)       3   0.01   1.41   (0.75--2.64)   3   0.09
                                                                                            Random effects   1.24            (0.55--2.77)                  1.52   (0.27--8.66)       
  P53     rs1042522       Pro72Arg     Arg/Arg             2982           4488              Fixed effects    0.97            (0.87--1.07)       4   0.52   0.97   (0.80--1.17)   4   0.07
                                                                                            Random effects   0.97            (0.82--1.14)                  0.97   (0.71--1.32)       
  ERCC2   rs28365048      Lys751Gln    Lys/Lys             2587           4771              Fixed effects    0.97            (0.86--1.09)       5   0.75   1.03   (0.88--1.21)   5   0.48
                                                                                            Random effects   0.97            (0.82--1.14)                  1.03   (0.83--1.29)       
  MGMT    rs1803965       171C \> T    C/C                 2310           3936              Fixed effects    0.98            (0.86--1.11)       3   0.61   1.05   (0.74--1.50)   3   0.21
                                                                                            Random effects   0.98            (0.73--1.30)                  1.06   (0.47--2.38)       
  MGMT    rs2308321       Ile143Val    Ile/Ile             2684           4349              Fixed effects    0.90            (0.79--1.02)       6   0.18   1.20   (0.81--1.79)   6   0.68
                                                                                            Random effects   0.90            (0.76--1.06)                  1.20   (0.71--2.02)       
  MGMT    rs12917         Leu84Phe     Leu/Leu             1455           3160              Fixed effects    0.79            (0.68--0.93)       5   0.79   1.40   (0.94--2.07)   5   0.69
                                                                                            Random effects   0.79            (0.64--0.99)                  1.40   (0.80--2.44)       
  OGG1    rs1052133       Ser326Cys    Ser/Ser             1680           4825              Fixed effects    0.95            (0.83--1.08)       5   0.89   0.98   (0.77--1.24)   5   0.67
                                                                                            Random effects   0.95            (0.79--1.14)                  0.98   (0.69--1.38)       
  XRCC1   rs1799782       Arg194Trp    Arg/Arg             1272           2984              Fixed effects    1.02            (0.83--1.26)       4   0.76   2.30   (1.13--4.67)   4   1.00
                                                                                            Random effects   1.02            (0.72--1.44)                  2.30   (0.73--7.26)       
  XRCC1   rs25489         Arg280His    Arg/Arg             903            2794              Fixed effects    1.12            (0.88--1.44)       2   0.84   2.87   (0.95--8.67)   2   0.21
                                                                                            Random effects   1.12            (0.23--5.58)                  2.87   (0.00--3719)       
  XRCC1   rs25487         Arg399Gln    Arg/Arg             2602           4255              Fixed effects    0.93            (0.83--1.03)       6   0.21   1.00   (0.84--1.19)   6   0.01
                                                                                            Random effects   0.93            (0.80--1.07)                  0.89   (0.58--1.37)       
  XRCC3   rs861539        Thr241Met    Thr/Thr             2707           4544              Fixed effects    0.96            (0.86--1.07)       7   0.14   0.90   (0.77--1.06)   7   0.88
                                                                                            Random effects   0.96            (0.84--1.10)                  0.90   (0.74--1.10)       

*OR adjusted for age, sex, country, and race*.

For the carcinogen metabolism SNPs, associations were observed between head and neck cancer risk and *ADH1B* Arg48His His/His homozygotes (OR = 2.7, 95% CI = 1.9--4.0), *ADH1C* Ile350Val rare homozygotes (OR = 1.2, 95% CI = 1.1--1.4), and the *GSTM1* null type (OR = 1.1, 95% CI = 1.0--1.2; Table [3](#T3){ref-type="table"}). Further adjusting for cigarette smoking and alcohol consumption (Table [A2](#TA2){ref-type="table"} in Appendix) did not change the results greatly. In addition, *XRCC1* Arg280His rare homozygotes showed an association with head and neck cancer risk after adjustment of cigarette smoking and alcohol consumption (OR = 3.3, 95% CI = 1.1--10).

###### 

**Carcinogen metabolism SNPs and the risk of head and neck cancer in the INHANCE consortium**.

  Gene     SNP rs number   Alteration          Referent genotype   No. Of cases   No. Of controls   Analysis model   Heterozygotes   Rare homozygotes                                            
  -------- --------------- ------------------- ------------------- -------------- ----------------- ---------------- --------------- ------------------ --- -------- ------ --------------- ---- ------
  MTHFR    rs1801131       Glu429Ala           Glu/Glu             830            2164              Fixed effects    0.90            (0.75--1.07)       2   0.14     0.95   (0.69--1.31)    2    0.25
                                                                                                    Random effects   0.90            (0.29--2.82)                    0.95   (0.12--7.66)         
  MTHFR    rs1801133       Ala222Val           Ala/Ala             2605           5444              Fixed effects    0.98            (0.88--1.09)       5   0.87     1.04   (0.88--1.23)    4    0.69
                                                                                                    Random effects   0.98            (0.85--1.14)                    1.04   (0.80--1.36)         
  ADH1B    rs1229984       Arg48His            His/His             2407           5408              Fixed effects    1.15            (0.92--1.43)       4   0.95     2.73   (1.87--3.98)    3    0.94
                                                                                                    Random effects   1.15            (0.80--1.65)                    2.73   (1.19--6.26)         
  ADH1C    rs698           Ile350Val           Ile/Ile             3306           6264              Fixed effects    1.06            (0.96--1.18)       9   0.42     1.22   (1.06--1.41)    9    0.09
                                                                                                    Random effects   1.06            (0.93--1.21)                    1.19   (0.94--1.50)         
  CYP1A1   E0322           3801T \> C          T/T                 1062           2657              Fixed effects    0.95            (0.80---1.14)      2   0.24     1.41   (0.94--2.12)    2    0.36
                                                                                                    Random effects   0.95            (0.30--2.98)                    1.41   (0.10--19.9)         
  CYP1A1   rs1048943       Ile462Val           Ile/Ile             2814           4823              Fixed effects    0.96            (0.81--1.14)       7   0.56     0.70   (0.35--1.43)    4    1.00
                                                                                                    Random effects   0.96            (0.77--1.19)                    0.70   (0.22--2.23)         
  CYP2E1   rs6413432       1143A \> T          A/A                 722            974               Fixed effects    1.20            (0.85--1.69)       2   0.13     1.39   (0.41--4.74)    2    0.60
                                                                                                    Random effects   1.21            (0.12--11.9)                    1.39   (0.00--3889)         
  CYP2E1   rs3813867       1293G \> C          G/G                 1789           3797              Fixed effects    0.86            (0.66--1.13)       5   0.72     1.65   (0.10--26.7)    4    1.00
                                                                                                    Random effects   0.86            (0.59--1.26)                    1.65   (0.02--151.9)        
  CYP2E1   rs2031920       1054C \> T          C/C                 981            1414              Fixed effects    1.18            (0.80---1.74)      4   0.66     1.66   (0.10--26.9)    4    1.00
                                                                                                    Random effects   1.18            (0.63--2.22)                    1.66   (0.02--152.7)        
  EPHX1    rs2234922       His139Arg           His/His             2840           4464              Fixed effects    0.94            (0.84--1.05)       6   0.25     1.24   (0.97--1.58)    6    0.25
                                                                                                    Random effects   0.94            (0.81--1.08)                    1.24   (0.89--1.71)         
  EPHX1    rs1051740       Tyr113His           Tyr/Tyr             2882           4923              Fixed effects    1.01            (0.91--1.11)       6   \<0.01   0.89   (0.75--1.05)    6    0.86
                                                                                                    Random effects   0.94            (0.71--1.26)                    0.89   (0.71--1.11)         
  GSTM1    NA              Null                present             3857           7232              Fixed effects    NA                                              1.11   (1.02--1.20)    12   0.33
                                                                                                    Random effects   NA                                              1.11   (1.00--1.23)         
  GSTM3    rs1799735       *Mnl*I AGG \> del   AGG/AGG             1039           2478              Fixed effects    1.02            (0.85--1.22)       3   0.38     0.90   (0.60--1.36)    3    0.72
                                                                                                    Random effects   1.02            (0.69--1.51)                    0.90   (0.37--2.23)         
  GSTP1    rs1799811       Ala114Val           Ala/Ala             2447           2757              Fixed effects    1.00            (0.85--1.18)       4   0.46     1.35   (0.77--2.35)    4    0.27
                                                                                                    Random effects   1.00            (0.76--1.31)                    1.35   (0.55--3.32)         
  GSTP1    rs947894        Ile105Val           Ile/Ile             4086           6461              Fixed effects    1.01            (0.93--1.11)       9   0.23     1.01   (0.88--1.16)    9    0.61
                                                                                                    Random effects   1.01            (0.91--1.13)                    1.01   (0.85--1.18)         
  GSTT1    NA              Null                present             3704           6919              Fixed effects    NA                                              0.91   (0.81--1.01)    11   0.13
                                                                                                    Random effects   NA                                              0.91   (0.78--1.05)         
  NQO1     rs1800566       Pro187Ser           Pro/Pro             1896           4038              Fixed effects    1.03            (0.91--1.17)       5   0.73     1.19   (0.88--1.61)    5    0.07
                                                                                                    Random effects   1.03            (0.86--1.23)                    1.21   (0.68--2.16)         

*OR adjusted for age, sex, country, and race*.

Table [4](#T4){ref-type="table"} shows the FPRP for the observed associations for the selected SNPS under a given range of probability of true associations. If the prior probability is greater than 10% and we assume the expected OR = 1.5, the FPRPs for *MGMT* Leu84Phe, *ADH1B* Arg48His, *ADH1C* Ile350Val, and *GSTM1* were lower than 20%.

###### 

**False positive report probabilities (FPRP) for observed associations for selected SNPs**.

  SNPs                    Ca     Co     OR     FPRP for OR = 1.5 and for different probabilities of a true association                   
  ------------- --------- ------ ------ ------ ------------------------------------------------------------------------- ------- ------- -------
  MGMT L84F     Leu/Phe   307    823    0.79   0.014                                                                     0.041   0.319   0.825
                Phe/Phe   43     81     1.40   0.302                                                                     0.565   0.935   0.993
  XRCC1 R194W   Arg/Trp   155    359    1.02   0.719                                                                     0.885   0.988   0.999
                Trp/Trp   16     21     2.30   0.349                                                                     0.617   0.947   0.994
  ADH1B R48H    Arg/His   467    1194   1.15   0.387                                                                     0.655   0.954   0.995
                His/His   1710   3018   2.73   0.001                                                                     0.002   0.019   0.161
  ADH1C I350V   Ile/Val   1383   2252   1.06   0.463                                                                     0.721   0.966   0.997
                Val/Val   579    778    1.22   0.021                                                                     0.060   0.413   0.877
  GSTM1         null      1906   3386   1.11   0.025                                                                     0.073   0.463   0.897

*OR adjusted for age, sex, country, race*.

Odds ratios for selected SNPs by head and neck cancer subsite are shown in Table [5](#T5){ref-type="table"}. *ADH1B* His48Arg and *ADH1C* Ile350Val were consistently associated with oral, pharyngeal, and oral/pharyngeal NOS cancer, but *ADH1C* Ile350Val was not associated with laryngeal cancer. The association of *GSTM1* null genotype was observed only with oral cancer (OR = 1.2 95% CI = 1.0--1.3).

###### 

**Selected SNPs and the risk of head and neck cancer by subsite**.

                           Oral OR (95% CI)    Pharynx OR (95% CI)   Oral/pharynx. NOS OR (95% CI)   Larynx OR (95% CI)
  ------------------------ ------------------- --------------------- ------------------------------- --------------------
  ADH1B His48Arg (ca/co)   541/5157            593/5157              208/5157                        981/5408
  His/His                  1.00                1.00                  1.00                            1.00
  His/Arg                  1.46 (0.86--2.47)   0.98 (0.61--1.27)     1.06 (0.68--1.64)               0.87 (0.56--1.34)
  Arg/Arg                  2.37 (1.31--4.30)   5.71 (3.22--10.1)     2.27 (1.14--4.52)               1.50 (0.67--3.38)
  P~trend~                 \<0.01              \<0.01                0.03                            0.08
  His/Arg or Arg/Arg       1.89 (1.29--2.78)   2.80 (2.00--3.92)     2.22 (1.34--3.69)               1.55 (1.16--2.07)
  ADH1C I350V (ca/co)      980/6013            1097/6013             240/6013                        940/5255
  Ile/Ile                  1.00                1.00                  1.00                            1.00
  Ile/Val                  1.18 (0.99--1.40)   1.10 (0.93--1.30)     1.16 (0.80--1.67)               0.90 (0.75--1.08)
  Val/Val                  1.40 (1.12--1.76)   1.22 (0.98--1.52)     2.08 (1.19--3.63)               1.11 (0.88--1.41)
  P~trend~                 0.01                \<0.01                0.22                            \<0.01
  Ile/Val or Val/Val       1.22 (1.04--1.44)   1.13 (0.97--1.32)     1.24 (0.87--1.76)               0.94 (0.80--1.12)
  GSTM1 (ca/co)            1236/6637           1068/5911             260/5911                        798/3620
  Present                  1.00                1.00                  1.00                            1.00
  Null                     1.15 (1.01--1.32)   0.95 (0.83--1.10)     1.06 (0.82--1.38)               1.06 (0.89--1.26)

*OR adjusted for age, sex, country, and race*.

Figure [1](#F1){ref-type="fig"} shows the stratified results for the selected SNPs, comparing the rare homozygotes to the common homozygotes. The effects from *ADH1B* Arg48His tended to be stronger among ever smokers and heavy drinkers than non-smokers and light drinkers. The associations from *ADH1C* Ile350Val were much stronger among Hispanic and Asian; however, these were based on relatively small numbers (case/control in the rare homozygotes: 16/10 for Hispanic and 2/3 for Asian).

![**Stratified analysis for selected SNPs: (A) ADH1B Arg48His; His/His vs. Arg/Arg (B) ADH1C Ile350Val: Val/Val vs. Ile/Ile; (C) GSTM1 null genotype**.](fonc-01-00013-g001){#F1}

Table [6](#T6){ref-type="table"} further evaluated the joint effects among smoking, drinking, and the selected SNPs. There was no evidence for the interaction between drinking and *ADH1B* Arg48His and *ADH1C* Ile350Val, and smoking and *GSTM1* on the risk of head and neck cancer.

###### 

**Joint effects of drinking and ADH1B Arg48His and ADH1C Ile350Val and smoking and GSTM1 on the risk of head and neck cancer**.

  Lifestyle                             SNP                  Case   Control   OR     95% CI
  ------------------------------------- -------------------- ------ --------- ------ --------------
  Drinking[\*](#t6fn1){ref-type="fn"}   ADH1B Arg48His                               
  Light                                 His/His or His/Arg   331    1773      1.00   
  Light                                 Arg/Arg              949    2186      1.73   (0.96--3.14)
  Heavy                                 His/His or His/Arg   292    503       1.96   (1.12--3.43)
  Heavy                                 Arg/Arg              711    552       4.03   (0.95--17.0)
                                        Interaction                           1.21   (0.43--3.41)
  Drinking[\*](#t6fn1){ref-type="fn"}   ADH1C Ile350Val                              
  Light                                 Ile/Ile or Ile/Val   1458   4004      1.00   
  Light                                 Val/Val              327    566       1.18   (0.88--1.59)
  Heavy                                 Ile/Ile or Ile/Val   906    893       2.45   (1.79--3.37)
  Heavy                                 Val/Val              197    117       2.42   (1.64--3.56)
                                        Interaction                           0.97   (0.62--1.52)
  Smoking                               GSTM1                                        
  No                                    Present              398    1414      1.00   
  No                                    Null                 385    1246      1.16   (0.94--1.42)
  Yes                                   Present              1328   1865      3.03   (1.78--5.17)
  Yes                                   Null                 1318   1761      3.11   (1.92--5.06)
                                        Interaction                           0.86   (0.66--1.12)

\**Heavy drinkers were defined as those who drank *\>* 40 ml/day*.

No obvious associations were observed for the haplotypes of *CYP2E1, EPHX1, GSTP1*, and *MTHFR* (data not shown).

Discussion
==========

Our results showed associations between head and neck cancer risk and genetic variants in *MGMT* Leu84Phe, *XRCC1* Arg194Trp, *ADH1B* Arg48His, *ADH1C* Ile350Val, and the *GSTM1*. Among them, the results for *XRCC1* Arg194Trp might be a false finding because the FPRP was high even if the prior probability was set to be high (0.25).

Among the four studies reported XRCC1 Arg194Trp, none of them were statistically significant with a total of 16 cases and 21 controls in the Trp/Trp group (Table [4](#T4){ref-type="table"}). In the International lung cancer consortium, which pooled five studies with 26 cases and 28 controls in the rare homozygote group, reported a non-statistically significant association with increased lung cancer risk (Hung et al., [@B34]). In a meta-analysis on DNA damage response genes and head and neck cancer reported an increased oral cancer risk for XRCC1 194Trp in the Asian population; however, no association was observed in the Caucasian population (Flores-Obando et al., [@B18]). A meta-analysis investigated the associations between DNA repair gene polymorphisms and smoking and found that XRCC1 194Trp, 280His, and 399Gln were associated with smoking behaviors (Hodgson et al., [@B29]). Nevertheless, further adjusted for smoking and drinking behaviors did not change the results materially, even though the association with 280His becomes statistically significant (Table [A2](#TA2){ref-type="table"} in Appendix). Further investigation into the XRCC1 function and its association in tobacco induced gene repair might be helpful to elucidate the associations with head and neck cancer risks.

Association between *MGMT* Leu84Phe and head and neck cancer risk was observed in the present report. The effects were similar regarding the cigarette smoking and alcohol drinking status, age, sex, and race (data not shown). The FPRP was 0.787 if the priority probability was very low (0.001). However, the associations between heterozygotes and rare homozygotes and head and neck cancer risk were in different directions. The results for the rare homozygotes were imprecise across the five studies provided the SNP (OR = 1.60, 0.90, 0.80, 1.55, and 0.66). Excluding the largest study which provided 608 cases and 1925 controls (OR = 1.60) in the analyses yield an OR 0f 0.99 (0.33--3.02). Nevertheless, the function of the *MGMT* Leu84Phe rare allele is not thought to differ from that of common homozygotes (based on the purified protein in the repair of *O*^6^-methylguanine *in vitro*; Pegg et al., [@B48]). In addition, more than 500 SNPs have been identified in *MGMT* in Caucasians and ∼60% of the identified SNPs have minor allele frequency greater than 0.05 (Bugni et al., [@B9]). The *MGMT* polymorphism might be associated with *MGMT* hypermethylation (Ogino et al., [@B42]), which could cause mutations in other critical genes (Mukai and Sekiguchi, [@B40]). The observed association might be a result of the mutated gene or an unidentified causal SNP. More studies would be needed to explore the associations and the mechanisms between *MGMT* polymorphisms and head and neck cancer.

Both *ADH1B* and *ADH1C* gene belongs to the ADH class I family, which plays a major role in ethanol metabolism (Edenberg, [@B16]). *ADH1C* 350Val and 272Arg result in a faster metabolism of ethanol (Hoog et al., [@B30]; Carr et al., [@B11]). Earlier associations on *ADH1B* and head and neck cancer were based on Asian studies (Hori et al., [@B31]; Yokoyama et al., [@B62], [@B63]; Asakage et al., [@B4]; Hiraki et al., [@B28]). Recently, two large case--control studies further confirmed the association in European populations (Hashibe et al., [@B22], [@B26]). The current analysis included the above studies; however, none of the study is influential on the overall pooled estimates. The differences in the published results could be because the frequency of the His allele is extremely low in the European population (International HapMap Project, [@B1]). In our study, only 1.2% European subjects carried the His/His genotype while 61.3% Asian participants had the polymorphism. Despite the differences in distribution, the effects from the SNP did not differ by populations (Figure [1](#F1){ref-type="fig"}). The effects from *ADH1B* Arg/Arg were stronger among ever smokers or heavy drinkers. People who carry the *ADH1B* Arg/Arg genotype also tended to consume more alcohol than those who carried the His/His or His/Arg genotype (Table [A3](#TA3){ref-type="table"} in Appendix).

Earlier studies found no association between *ADH1C* Ile350Val and head and neck cancers (Coutelle et al., [@B12]; Bouchardy et al., [@B8]; Olshan et al., [@B44]; Sturgis et al., [@B56]; Wang et al., [@B60]) while some recent studies reported associations as main effects or combined effects with alcohol drinking (Harty et al., [@B21]; Peters et al., [@B49]; Hashibe et al., [@B22]). A large study (Hashibe et al., [@B26]) combining data from Europe and Latin America further suggested associations of *ADH1B, ADH1C*, and *ADH7* genes with head and neck cancer risk. In the present pooled analysis, which combined data from Europe, North America, Latin America, and Asia, we observed an overall 25% increased risk of head and neck cancer on *ADH1C* Ile350Val, especially among oral and pharyngeal cancer patients. The result from Asia was very unstable possibly due to the low frequency of the homozygotes in the population. Excluding the Asian study from the analysis did not change the results materially.

*ADH1B* Arg48His and *ADH1C* Ile350Val genes are only 100 kb away and have strong linkage disequilibrium (LD \> 0.65; International HapMap Project, [@B1]). However, after restriction to the *ADH1B* His/His or His/Arg population, *ADH1C* Val/Val still showed strong association on head and neck cancer risk. The frequency was very low in the European population and thus the statistical power was low (data not shown).

*GSTM1* belongs to the glutathione *S*-transferases (GST) family producing phase II xenobiotic metabolic enzymes. The GSTs play a role in the metabolism of chemical carcinogens, especially with regard to those present in tobacco smoke (Peters et al., [@B50]). However, epidemiological studies on the associations between GSTs and head and neck cancer have been inconsistent. The inconsistency could be attributed to study design, for example, population-based controls vs. hospital-based controls, matching criteria, and incident cases vs. prevalent cases (Geisler and Olshan, [@B20]). The GST enzymes are also known to be expressed differently by site (Pacifici et al., [@B45]; Moscow et al., [@B39]; Howie et al., [@B32]). In the present study, *GSTM1* null genotype was associated with oral cavity cancer but not the other head and neck cancer sites.

Interestingly, race seems to be a potential effect modifier for the association between *GSTM1* and head and neck cancer, with ORs of 1.1 for Whites, Blacks, and Hispanic and 1.3 for Asians, even though the CI overlapped. The OR for Asians in North America was 1.3 (case/control: 28/64, 95% CI = 0.11--16).

In addition, significant results were only observed in the hospital-based studies for the association between *GSTM1* and head and neck cancer. Hospital-based studies in our study exclude individuals with previous or malignant disease, including respiratory disease (France, Rome, North Carolina, Northeast US, India), tobacco or alcohol related diseases (Central Europe and Western Europe) or from hospital visitors (Houston). The *GSTM1* genotype distribution among the hospital-based controls may not reflect those of the base population in our study. Among controls, the hospital-based studies had lower frequency of the null type *GSTM1* than population-based studies (45 vs. 52%, *p* \< 0.0001).

A limitation of our study is that the pooled analysis is based on a heterogeneous population from different geographic regions and ethnicities. However, heterogeneity across studies was not significant for most of our results. In addition, stratified analysis was conducted to assess whether our observations were due to a specific geography and ethnicity. In addition, individual data was available and were harmonized according to standard protocol; thus, we were able to control the potential confounders consistently.

A genome-wide association study (GWAS) was performed independently within the INHANCE consortium using HumanHap300 platform (McKay et al., [@B38]). The GWAS used the Central Europe and Western Europe studies for the discovery phase and replicated the findings in another subset of the INHANCE consortium: Los Angeles, Houston, Latin America, IARC Multicenter, Boston, and Rome studies, in combination with additional studies not in the current pooled analyses. The *ADH1C* Ile350Val was strongly associated with the head and neck cancer in the discovery phase (*p* \< 10^−5^) and was replicated in the replication phase. The *ADH1B* His48Arg was not tagged on HumanHap300 but was selected as a candidate gene for the replication and showed the strongest association in the replication phase (*p* = 3 × 10^−12^). Inconsistency has been observed between results from candidate gene approach and from GWAS in previous studies (Siontis et al., [@B53]). The consistent findings in the two ADH SNPs in both GWAS (McKay et al., [@B38]) and a previous analyses (Hashibe et al., [@B22]) as well as the current pooled analyses based on candidate gene approach further support the role of alcohol metabolism genes on the head and neck cancer etiology. Our observations suggest that, while GWAS may lead to novel hypotheses by elucidating new disease associated loci, traditional hypotheses-driven associations should not be ignored.

In summary, we observed associations between *ADH1B* Arg48His, *ADH1C* Ile350Arg, *GSTM1* null and head and neck cancer risk. An association for *XRCC1* Arg194Trp was not well supported based on the FPRPs. Further investigation is needed for *MGMT* Leu84Phe for the mechanism. *ADH1B* Arg48His and *ADH1C* Ile350Arg could be risk factors or markers of other risk genes for head and neck cancer. Effect of *GSTM1* is slightly associated with increased risk of head and neck cancer but inconsistent across subsites.
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###### 

**Summary of individual studies involved in the current analysis**.

  Study location (reference[^†^](#tafn1){ref-type="fn"})                                                                        Recruitment period   Platform/method¥                                                                                       Case subjects     Control subjects[^‡^](#tafn2){ref-type="fn"}                                                              
  ----------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------------------------------------------------------------------------------------------ ----------------- ---------------------------------------------- -------- ------------------------------------------------- ------------------------------------
  **Europe**                                                                                                                                                                                                                                                                                                                                                                            
  Paris, France (Benhamou et al., [@B5])                                                                                        1987--1992           PCR-RFLP                                                                                               Hospital          95[^§^](#tafn3){ref-type="fn"}                 NA       Hospital (unhealthy)                              95[^§^](#tafn3){ref-type="fn"}
  Central Europe (Banska Bystrica, Bucharest, Budapest, Lodz, Moscow)[^\|\|^](#tafn4){ref-type="fn"} (Hashibe et al., [@B22])   1998--2003           TaqMan                                                                                                 Hospital          96                                             ≥15      Hospital (unhealthy)                              97
  Rome (Boccia et al., [@B7])                                                                                                   2002--2007           PCR-RFLP                                                                                               Hospital          98                                             NA       Hospital (unhealthy)                              94
  Western Europe (Canova et al., [@B10])                                                                                        2000--2005           APEX                                                                                                   Hospital          82                                                      Hospital (unhealthy)[\*](#tafn6){ref-type="fn"}   68
  Heidelberg, Germany (Risch et al., [@B51])                                                                                    1998--2000           PCR-RFLP                                                                                               Hospital          96                                             \<80     Population registry                               62
  **North America**                                                                                                                                                                                                                                                                                                                                                                     
  Seattle, WA Crump et al. ([@B13]), Huang et al. ([@B33]), Schwartz et al. ([@B52])                                            1985--1995           PCR-RFLP, multiplex, or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry   Cancer registry   54.4, 63.3[^¶^](#tafn5){ref-type="fn"}         18--65   Random digit dialing                              63, 61[^¶^](#tafn5){ref-type="fn"}
  Iowa (Wang et al., [@B60])                                                                                                    1993--2006           PCR-RFLP                                                                                               Hospital          87                                             \>17     Hospital (healthy)                                92
  North Carolina (Olshan et al., [@B43])                                                                                        1994--1997           Multiplex                                                                                              Hospital          88                                             \>17     Hospital (unhealthy)                              86
  Los Angeles, CA (Cui et al., [@B14])                                                                                          1999--2004           PCR-RFLP                                                                                               Cancer registry   49                                             18--65   Neighborhood                                      67.5
  Houston, TX (Zhang et al., [@B64])                                                                                            2001--2006           PCR-RFLP                                                                                               Hospital          95                                             ≥18      Hospital visitors                                 \>80
  Northeast, US (Park et al., [@B46])                                                                                           1994--2000           PCR-RFLP                                                                                               Hospital                                                         NA       Hospital (unhealthy)                              
  **Latin America**                                                                                                                                                                                                                                                                                                                                                                     
  Puerto Rico (Hayes et al., [@B27])                                                                                            1992--1995           PCR-RFLP or TaqMan                                                                                     Cancer registry   71                                             21--79   Residential records                               83
  **Asia**                                                                                                                                                                                                                                                                                                                                                                              
  India (Anantharaman et al., [@B3])                                                                                            2001--2004           PCR-RFLP                                                                                               Hospital                                                         NA       Hospital (unhealthy)                              
  Japan (Suzuki et al., [@B58])                                                                                                 2001--2005           TaqMan                                                                                                 Hospital          61                                             20--79   Hospital (unhealthy)                              41

*NA = not applicable/not available*.

^†^*Representative publication in which study methods are described*.

^‡^*All studies frequency matched control subjects to case subjects on age and sex. Additional frequency matching factors included study center (Central Europe), hospital (France study), ethnicity (Northeast US), neighborhood (Los Angeles study), and tobacco and alcohol habits (India)*.

^§^*Participation rate was not formally assessed, estimated response rate reported*.

^\|\|^*Multicenter study*.

^¶^*Two response rates are reported because data were collected in two population-based case--control studies, the first from 1985 to 1989 among men and the second from 1990 to 1995 among men and women*.

\**The three UK centers (Glasgow, Manchester, and Newcastle) from the Western European study were chosen from the same family medical practice (population-based)*.

###### 

**Single nucleotide polymorphisms and the risk of head and neck cancer, adjusted for smoking and drinking (exclude Northeast US study)**.

  Gene     SNP rs number   Alteration          Referent genotype   Analysis model   Heterozygotes   Rare homozygotes                                          
  -------- --------------- ------------------- ------------------- ---------------- --------------- ------------------ --- ------ ------ --------------- ---- ------
  P21      rs1801270       Ser31Arg            Ser/Ser             Fixed effects    1.14            (0.96--1.36)       3   0.01   1.59   (0.81--3.12)    3    0.14
                                                                   Random effects   1.24            (0.60--2.56)                  1.62   (0.32--8.19)         
  P53      rs1042522       Pro72Arg            Arg/Arg             Fixed effects    0.96            (0.86--1.08)       4   0.48   0.96   (0.78--1.18)    4    0.28
                                                                   Random effects   0.96            (0.80--1.15)                  0.96   (0.69--1.35)         
  ERCC2    rs28365048      Lys751Gln           Lys/Lys             Fixed effects    0.95            (0.84--1.09)       5   0.53   1.06   (0.89--1.25)    5    0.63
                                                                   Random effects   0.95            (0.79--1.15)                  1.06   (0.83--1.35)         
  MGMT     rs1803965       171C\> T            C/C                 Fixed effects    0.97            (0.84--1.11)       3   0.58   1.03   (0.70--1.53)    3    0.08
                                                                   Random effects   0.97            (0.71--1.32)                  1.08   (0.33--3.58)         
  MGMT     rs2308321       Ile143Val           Ile/Ile             Fixed effects    0.90            (0.78--1.03)       6   0.52   1.32   (0.85--2.04)    6    0.66
                                                                   Random effects   0.90            (0.75--1.07)                  1.32   (0.75--2.34)         
  MGMT     rs12917         Leu84Phe            Leu/Leu             Fixed effects    0.80            (0.68--0.95)       5   0.66   1.49   (0.96--2.30)    5    0.83
                                                                   Random effects   0.80            (0.63--1.02)                  1.49   (0.80--2.76)         
  OGG1     rs1052133       Ser326Cys           Ser/Ser             Fixed effects    0.95            (0.82--1.09)       5   0.95   1.00   (0.77--1.30)    5    0.62
                                                                   Random effects   0.95            (0.78--1.16)                  1.00   (0.70--1.45)         
  XRCC1    rs1799782       Arg194Trp           Arg/Arg             Fixed effects    0.94            (0.74--1.18)       4   0.89   2.31   (1.04--5.11)    4    0.98
                                                                   Random effects   0.94            (0.64--1.37)                  2.31   (0.64--8.40)         
  XRCC1    rs25489         Arg280His           Arg/Arg             Fixed effects    1.09            (0.84--1.43)       2   0.87   3.28   (1.06--10.2)    2    0.20
                                                                   Random effects   1.09            (0.19--6.24)                  3.28   (0.00--5008)         
  XRCC1    rs25487         Arg399Gln           Arg/Arg             Fixed effects    0.94            (0.83--1.06)       6   0.48   0.99   (0.82--1.21)    6    0.02
                                                                   Random effects   0.94            (0.80--1.10)                  0.97   (0.72--1.30)         
  XRCC3    rs861539        Thr241Met           Thr/Thr             Fixed effects    0.98            (0.87--1.10)       7   0.06   0.97   (0.81--1.16)    7    0.70
                                                                   Random effects   0.98            (0.84--1.14)                  0.97   (0.78--1.21)         
  MTHFR    rs1801131       Glu429Ala           Glu/Glu             Fixed effects    0.87            (0.71--1.05)       2   0.21   0.83   (0.59--1.19)    2    0.29
                                                                   Random effects   0.87            (0.25--3.00)                  0.83   (0.08--8.31)         
  MTHFR    rs1801133       Ala222Val           Ala/Ala             Fixed effects    1.03            (0.92--1.16)       5   0.92   1.04   (0.87--1.25)    4    0.33
                                                                   Random effects   1.03            (0.88--1.22)                  1.04   (0.78--1.40)         
  ADH1B    rs1229984       Arg48His            Arg/Arg             Fixed effects    1.04            (0.82--1.32)       4   0.95   2.35   (1.57--3.53)    3    0.93
                                                                   Random effects   1.04            (0.71--1.53)                  2.35   (0.97--5.74)         
  ADH1C    rs1042758       Ile350Val           Ile/Ile             Fixed effects    1.01            (0.90--1.14)       9   0.68   1.20   (1.03--1.40)    9    0.22
                                                                   Random effects   1.01            (0.89--1.16)                  1.17   (0.93--1.46)         
  CYP1A1   E0322           3801T \> C          T/T                 Fixed effects    0.97            (0.80--1.18)       2   0.87   1.52   (0.94--2.47)    2    0.28
                                                                   Random effects   0.97            (0.27--3.53)                  1.52   (0.07--34.9)         
  CYP1A1   rs1048943       Ile462Val           Ile/Ile             Fixed effects    0.97            (0.80--1.18)       7   0.72   0.84   (0.39--1.79)    4    0.99
                                                                   Random effects   0.97            (0.76--1.24)                  0.84   (0.25--2.86)         
  CYP2E1   rs6413432       1143A \> T          A/A                 Fixed effects    1.32            (0.89--1.96)       2   0.06   1.25   (0.30--5.22)    2    0.97
                                                                   Random effects   1.38            (0.05--40.2)                  1.25   (0.00--13439)        
  CYP2E1   rs3813867       1293G \> C          G/G                 Fixed effects    0.74            (0.53--1.04)       4   0.88   4.44   (0.27--72.7)    3    1.00
                                                                   Random effects   0.74            (0.43--1.27)                  4.44   (0.01--2051)         
  CYP2E1   rs2031920       1054C \> T          C/C                 Fixed effects    1.15            (0.68--1.95)       3   0.25   4.45   (0.27--72.7)    3    1.00
                                                                   Random effects   1.15            (0.36--3.66)                  4.45   (0.01--2052)         
  EPHX1    rs2234922       His139Arg           His/His             Fixed effects    0.92            (0.82--1.04)       6   0.82   1.31   (1.00--1.72)    6    0.24
                                                                   Random effects   0.92            (0.79--1.08)                  1.31   (0.92--1.87)         
  EPHX1    rs1051740       Tyr113His           Tyr/Tyr             Fixed effects    0.98            (0.88--1.10)       6   0.01   0.86   (0.71--1.04)    6    0.56
                                                                   Random effects   0.92            (0.70--1.22)                  0.86   (0.67--1.10)         
  GSTM1    NA              null                present             Fixed effects    NA                                            1.08   (0.98--1.19)    11   0.45
                                                                   Random effects   NA                                            1.08   (0.96--1.22)         
  GSTM3    rs1799735       *Mnl*I AGG \> del   AGG/AGG             Fixed effects    1.03            (0.83--1.27)       2   0.15   0.81   (0.43--1.50)    2    0.44
                                                                   Random effects   1.03            (0.25--4.16)                  0.81   (0.01--46.1)         
  GSTP1    rs1799811       Ala114Val           Ala/Ala             Fixed effects    1.04            (0.87--1.25)       3   0.60   1.21   (0.65--2.24)    3    0.18
                                                                   Random effects   1.04            (0.69--1.56)                  1.20   (0.27--5.38)         
  GSTP1    rs947894        Ile105Val           Ile/Ile             Fixed effects    1.02            (0.92--1.12)       8   0.35   0.95   (0.81--1.11)    8    0.40
                                                                   Random effects   1.02            (0.90--1.14)                  0.95   (0.79--1.15)         
  GSTT1    NA              null                present             Fixed effects    NA                                            0.92   (0.82--1.04)    11   0.13
                                                                   Random effects   NA                                            0.92   (0.80--1.06)         
  NQO1     rs1800566       Pro187Ser           Pro/Pro             Fixed effects    1.02            (0.89--1.17)       5   0.68   1.07   (0.77--1.49)    5    0.01
                                                                   Random effects   1.02            (0.84--1.24)                  1.11   (0.52--2.37)         

*OR adjusted for age, sex, country, race, pack years of smoking, and alcohol drinking. Data from Northeast US were excluded because of missing in alcohol drinking*.

###### 

**Mean and median of alcohol drinking (ml/day) by ADH1B Are48His genotype**.

  Study            Allele               Mean    Median   *p*
  ---------------- -------------------- ------- -------- --------
  Central Europe   His/His or His/Arg   25.28   13.17    0.42
                   Arg/Arg              25.01   11.36    
  Western Europe   His/His or His/Arg   21.12   9.47     0.01
                   Arg/Arg              27.04   15.92    
  Heidelberg       His/His or His/Arg   45.96   27.69    
                   Arg/Arg              NA      NA       
  Japan            His/His or His/Arg   23.58   7.92     \<0.01
                   Arg/Arg              28.71   23.76    

*p-value was determined by Wilcoxon rank sum test*.
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